II. Please design five reading comprehensive questions based on the passage aligned with the format of the GSAT questions. The questions should test various reading skills, with the first
two focusing on identifying the main idea and making inferences. At least three different question types must be included (e.g., multiple-choice, matching, sequencing, fill-in-the-blanks,
completion of tables/charts/graphic organizers, or short-answer questions). Please provide an answer key. 

Recent studies suggest that GLP-1 drugs, originally designed for diabetes and weight loss, mayoffer a groundbreaking approach to treating addiction. A comprehensive study reveals that these
medications could reduce the risk of developing substance use disorders and minimize the severe consequences of addictive behaviors.

The research team, led by Dr. Ziyad Al-Aly, analyzed health records from over 600,000 patients. They compared GLP-1 users with those taking SGLT2 inhibitors. Unlike SGLT2 drugs, which
primarily affect the kidneys to remove excess sugar, GLP-1 medications target the mesolimbic system in the brain. This region governs reward signals that reinforce cravings for food, alcohol,
nicotine, and opioids. By suppressing these signals, GLP-1 drugs effectively "quiet" the brain's desire for addictive substances by suppressing the "food noise" or craving signals that lead to
dependency.

The results were significant. Compared to people prescribed an SGLT2 inhibitor, participants taking GLP-1 drugs showed a 14% to 25% lower risk of developing new addictions. For those
already struggling with substance abuse, the drugs were associated with a 39% reduction in overdoses and a 50% decrease in drug-related deaths. "There is no precedent in our medical toolkit
for a single medicine that works across such a wide range of addictive substances," Al-Aly noted.

Despite these promising findings, experts remain cautious about the long-term implications. One major concern is the "rebound effect." Similar to weight loss patients regaining weight after
stopping the medication, addiction cravings might return "with a vengeance" once the drug is discontinued. Furthermore, it remains unclear whether the brain will develop a tolerance to the treatment over time. Scientists still need to determine the ideal dose and duration required to maintain these benefits safely.

While Dr. Al-Aly says that if people qualify for the drugs because they have diabetes or are overweight or obese, and they also want to quit smoking, stop drinking, or control their opioid
dependence, then the GLP-1 medications could help. Further research is needed to resolve these uncertainties before GLP-1 can be officially established as a new class of anti-addiction medication.

Adapted from:      https://time.com/7382492/weight-loss-drugs-prevent-treat-addiction-study/